An FDA First Adds To Rock Creek’s Regulatory Adventures
This article was originally published in The Tan Sheet
Executive Summary
FDA “for the first time” notified tobacco retailers about products found to be not substantially equivalent for sale, with each of the 16 warnings identifying Rock Creek’s Ariva and Stonewall Jackson nicotine lozenges. The firm continues turning its operations to drug development after FDA rejected a NDI notification.